Ligand Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell LGND and other ETFs, options, and stocks.

About LGND

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that involves clinical development and commercialization of high-value medicines. Its platforms, Captisol and NITRICI, offer technology with broad applicability in drug development to a large network of biopharmaceutical partners, including the largest pharmaceutical manufacturers in the world. 

CEO
Todd Christopher Davis
CEOTodd Christopher Davis
Employees
47
Employees47
Headquarters
Jupiter, Florida
HeadquartersJupiter, Florida
Founded
1987
Founded1987
Employees
47
Employees47

LGND Key Statistics

Market cap
6.02B
Market cap6.02B
Price-Earnings ratio
32.24
Price-Earnings ratio32.24
Dividend yield
—
Dividend yield—
Average volume
256.42K
Average volume256.42K
High today
$305.35
High today$305.35
Low today
$293.90
Low today$293.90
Open price
$303.17
Open price$303.17
Volume
297.78K
Volume297.78K
52 Week high
$326.63
52 Week high$326.63
52 Week low
$166.10
52 Week low$166.10

Stock Snapshot

As of today, Ligand Pharmaceuticals(LGND) shares are valued at $301.52. The company's market cap stands at 6.02B, with a P/E ratio of 32.24.

During the trading session on 2026-09-26, Ligand Pharmaceuticals(LGND) shares reached a daily high of $305.35 and a low of $293.90. At a current price of $301.52, the stock is +2.6% higher than the low and still -1.3% under the high.

Trading activity shows a volume of 297.78K, compared to an average daily volume of 256.42K.

The stock's 52-week range extends from a low of $166.10 to a high of $326.63.

The stock's 52-week range extends from a low of $166.10 to a high of $326.63.

LGND News

Nasdaq 13h
Barclays Initiates Coverage of Ligand Pharmaceuticals Incorporated - Equity Right at Overweight

Fintel reports that on September 25, 2026, Barclays initiated coverage of Ligand Pharmaceuticals Incorporated - Equity Right (OTCPK:LGNXZ) with an Overweight re...

Barclays Initiates Coverage of Ligand Pharmaceuticals Incorporated - Equity Right at Overweight
TipRanks 2d
Ligand Pharma Announces $47 Million AvenCell Financing Deal

An update from Ligand Pharma ( (LGND) ) is now available. On September 24, 2026, Ligand Pharmaceuticals announced a financing agreement with AvenCell Therapeut...

Nasdaq 2d
Ligand Commits Upto $47 Mln To AvenCell Cancer Cell Therapy

(RTTNews) - Thursday, Ligand Pharmaceuticals Inc. (LGND) announced a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell therapy company...

Ligand Commits Upto $47 Mln To AvenCell Cancer Cell Therapy

Analyst ratings

100%

of 11 ratings
Buy
100%
Hold
0%
Sell
0%

More LGND News

Simply Wall St 3d
How Investors Are Reacting To Ligand Pharmaceuticals Ryjunea Royalty Rights Deal

Ligand Pharmaceuticals agreed to pay Sydnexis US$23 million upfront to acquire a 100% royalty interest on Ryjunea net sales in Europe, the Middle East, and Afri...

How Investors Are Reacting To Ligand Pharmaceuticals Ryjunea Royalty Rights Deal
Nasdaq 4d
Ligand Buys Royalty Rights In Santen's Ryjunea Eye Drug

(RTTNews) - Ligand Pharmaceuticals Inc. (LGND), announced on Tuesday that it has acquired royalty and milestone payment rights tied to Santen Pharmaceutical Co....

Ligand Buys Royalty Rights In Santen's Ryjunea Eye Drug
TipRanks 4d
Ligand Pharma Expands Ophthalmology Royalties With Ryjunea Deal

Ligand Pharma ( (LGND) ) has shared an update. Ligand Pharmaceuticals is a U.S.-based biopharmaceutical royalty aggregator that finances and advances late-stag...

Benzinga 5d
Here’s How Much You Would Have Made Owning Ligand Pharmaceuticals Stock In The Last 5 Years - Benzinga

...

Here’s How Much You Would Have Made Owning Ligand Pharmaceuticals Stock In The Last 5 Years - Benzinga

People also own

Based on the portfolios of people who own LGND. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.